The updated results from the iMMagine-1 study showed that Anito-cel continues to exhibit strong safety and efficacy profiles. Notably, there were no reports of delayed neurotoxicity or ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to ...

The recent event at ASH 2024 highlighted the positive safety profile of anito-cel, especially in terms of avoiding delayed or non-ICANS neurotoxicity. This aspect of safety is seen as a ...

Arcellx's anito-cel shows 97% overall response rate and 62% CR/sCR rate in high-risk RRMM patients during Phase 2 iMMagine-1 trial. No severe neurotoxicities observed in over 150 patients dosed ...

And particularly we're interested in two molecules. One was the artist formerly known as ABBV-383 as a new bispecific antibody, and then anito-cel as a CAR-T. So let's start with the bispecific ...